Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study. [electronic resource]
Producer: 20080722Description: 167-72 p. digitalISSN:- 1537-162X
- Adjuvants, Immunologic -- therapeutic use
- Disability Evaluation
- Dose-Response Relationship, Drug
- Humans
- Injections, Subcutaneous
- Interferon beta-1a
- Interferon-beta -- therapeutic use
- Multiple Sclerosis, Relapsing-Remitting -- diagnosis
- Patient Satisfaction
- Prospective Studies
- Recurrence
- Self Administration -- instrumentation
- Severity of Illness Index
- Surveys and Questionnaires
- Syringes
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.